Neoadjuvant NabPE With or Without Serplulimab for Early-stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Breast cancer-an Observational Real-world Study.
Latest Information Update: 05 Feb 2025
Price :
$35 *
At a glance
- Drugs Epirubicin (Primary) ; Paclitaxel (Primary) ; Serplulimab (Primary)
- Indications HER2 negative breast cancer
- Focus Therapeutic Use
- 23 Jan 2025 New trial record